Bronchodilators in cystic fibrosis

Journal of the Royal Society of Medicine, Supplement

Volumn 93, Issue 38, 2000, Pages 37-39

  Brand, Paul L P ^a  

^a ISALA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; FENOTEROL; FORMOTEROL; IPRATROPIUM BROMIDE; SALBUTAMOL; SALMETEROL; TERBUTALINE;

AIRWAY OBSTRUCTION; ASTHMA; CLINICAL TRIAL; CONFERENCE PAPER; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FORCED EXPIRATORY VOLUME; HUMAN; PHYSIOTHERAPY;

ADOLESCENT; ADULT; ALBUTEROL; BRONCHODILATOR AGENTS; CHILD, PRESCHOOL; CHRONIC DISEASE; CLINICAL TRIALS; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE;

EID: 0034103455     PISSN: 02675331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR. Investigators and coordinators of the epidemiologic study of cystic fibrosis. Patterns of medical practice in cystic fibrosis: Part II. Use of therapies. Pediatr Pulmonol 1999;28:248-54
2. Cropp GJ. Effectiveness of bronchodilators in cystic fibrosis. Am J Med 1996;100:19S-29S
3. van Haren EHJ, Lammers J-WJ, Festen J, van Herwaarden CLA. Bronchial vagal tone and responsiveness to histamine, exercise and bronchodilators in adult patients with cystic fibrosis. Eur Respir J 1992;5:1083-8
4. Macfarlane PI, Heaf D. Changes in airflow obstruction and oxygen saturation in response to exercise and bronchodilators in cystic fibrosis. Pediatr Pulmonol 1990;8:4-11
5. Wood RE, Wanner A, Hirsch J, Farrell PM. Tracheal mucociliary transport in patients with cystic fibrosis and its stimulation by terbutaline. Am Rev Respir Dis 1975;111:733-8
6. Mortensen J, Hansen A, Falk M, Nielsen IK, Groth S. Reduced effect of inhaled beta-2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. Chest 1993;103:805-11
7. Hordvik NL, König P, Morris D, Kreutz C, Barbero GJ. A longitudinal study of bronchodilator responsiveness in cystic fibrosis. Am Rev Respir Dis 1985;131:889-93
8. Eber E, Oberwalder B, Zach MS. Airway obstruction and airway wall instability in cystic fibrosis: the isolated and combined effect of theophylline and sympathicomimetics. Pediatr Pulmonol 1988;4:205-12
9. Hellinckx J, de Boeck K, Demedts M. No paradoxical bronchodilator response with forced oscillation technique in children with cystic fibrosis. Chest 1998;113:55-9
10. Hordvik NL, Sammut PH, Judy CG, Strizek SJ, Colombo JL. The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med 1996;154:156-60
11. Finnegan MJ, Hughes DV, Hodson ME. Comparison of nebulized and intravenous terbutaline during exacerbations of pulmonary infection in patients with cystic fibrosis. Eur Respir J 1992;5:1089-91
12. Bargon VJ, Viel K, Dauletbaev N, Wiewrodt R, Buhl R. Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients. Eur Respir J 1997;10:2307-11
13. Hordvik NL, Sammut PH, Judy CG, Colombo JL. Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis. Pediatr Pulmonol 1999;27:43-53
14. Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99:1088-92
15. König P, Poehler J, Barbero GJ. A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatr Pulmonol 1998;25:32-6